This report describes two subsequent liver-small bowel-pancreas-kidney (multivisceral) transplantations in a child colonized with multidrug-resistant Pseudomonas aeruginosa. We discuss the dilemma concerning the transplantation of patients colonized with multidrug-resistant Pseudomonas spp., its potential consequences, and the peri and postoperative management of these patients.
Get full access to this article
View all access options for this article.
References
1.
DobbinC., MaleyM., HarknessJ., BennR., MaloufM., GlanvilleA., ByeP.2004. The impact of pan-resistant bacterial pathogens on survival after lung transplantation in cystic fibrosis: results from a single large referral centre. J. Hosp. Infect., 56:277–282.
2.
DunhamS.A., McPhersonC.J., MillerA.A.2010. The relative contribution of efflux and target gene mutations to fluoroquinolone resistance in recent clinical isolates of Pseudomonas aeruginosa. Eur. J. Clin. Microbiol. Infect. Dis., 29:279–288.
3.
Giamarellos-BourboulisE.J., SambatakouH., GalaniI., GiamarellouH.2003. In vitro interaction of colistin and rifampin on multidrug-resistant Pseudomonas aeruginosa. J. Chemother., 15:235–238.
4.
HadjiliadisD., SteeleM.P., ChaparroC., SingerL.G., WaddellT.K., HutcheonM.A., DavisR.D., TullisD.E., PalmerS.M., KeshavjeeS.2007. Survival of lung transplant patients with cystic fibrosis harboring panresistant bacteria other than Burkholderia cepacia, compared with patients harboring sensitive bacteria. J. Heart Lung Transplant, 26:834–838.
5.
ImamuraY., HigashiyamaY., TomonoK., IzumikawaK., YanagiharaK., OhnoH., MiyazakiY., HirakataY., MizutaY., KadotaJ., IglewskiB.H., KohnoS.2005. Azithromycin exhibits bactericidal effects on Pseudomonas aeruginosa through interaction with the outer membrane. Antimicrob. Agents Chemother., 49:1377–1380.
6.
KanellakopoulouK., SarafisP., GalaniI., GiamarellouH., Giamarellos-BourboulisE.J.2008. In vitro synergism of beta-lactams with ciprofloxacin and moxifloxacin against genetically distinct multidrug-resistant isolates of Pseudomonas aeruginosa. Int. J. Antimicrob. Agents, 32:33–39.
7.
LandmanD., BratuS., AlamM., QualeJ.2005. Citywide emergence of Pseudomonas aeruginosa strains with reduced susceptibility to polymyxin B. J. Antimicrob. Chemother., 55:954–957.
8.
LivermoreD.M.2002. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?Clin. Infect. Dis., 34:634–640.
9.
MeacheryG., De SoyzaA., NicholsonA., ParryG., HasanA., TocewiczK., PillayT., ClarkS., LordanJ.L., SchuelerS., FisherA.J., DarkJ.H., GouldF.K., CorrisP.A.2008. Outcomes of lung transplantation for cystic fibrosis in a large UK cohort. Thorax, 63:725–731.
10.
NaginoK., KobayashiH.1997. Influence of macrolides on mucoid alginate biosynthetic enzyme from Pseudomonas aeruginosa. Clin. Microbiol. Infect., 3:432–439.
11.
NalcaY., JanschL., BredenbruchF., GeffersR., BuerJ., HausslerS.2006. Quorum-sensing antagonistic activities of azithromycin in Pseudomonas aeruginosa PAO1: a global approach. Antimicrob. Agents Chemother., 50:1680–1688.
12.
NguyenD., EmondM.J., Mayer-HamblettN., SaimanL., MarshallB.C., BurnsJ.L.2007. Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatr. Pulmonol., 42:533–541.
13.
PankuchG.A., LinG., SeifertH., AppelbaumP.C.2008. Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii. Antimicrob. Agents Chemother., 52:333–336.
14.
ReinhardtA., KohlerT., WoodP., RohnerP., DumasJ.L., RicouB., van DeldenC.2007. Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. Antimicrob. Agents Chemother., 51:1341–1350.
15.
RhombergP.R., JonesR.N.2009. Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999–2008)Diagn. Microbiol. Infect. Dis., 65:414–426.
16.
StratevaT., YordanovD.2009. Pseudomonas aeruginosa—a phenomenon of bacterial resistance. J. Med. Microbiol., 58:1133–1148.
17.
TamaokiJ.2004. The effects of macrolides on inflammatory cells. Chest., 125:41S–50Squiz 51S.
18.
TanT.Y., NgS.Y.2006. The in-vitro activity of colistin in gram-negative bacteria. Singapore Med. J., 47:621–624.
19.
TsaiW.C., RodriguezM.L., YoungK.S., DengJ.C., ThannickalV.J., TatedaK., HershensonM.B., StandifordT.J.2004. Azithromycin blocks neutrophil recruitment in Pseudomonas endobronchial infection. Am. J. Respir. Crit. Care Med., 170:1331–1339.
20.
TurnerP.J.2009. MYSTIC Europe 2007: activity of meropenem and other broad-spectrum agents against nosocomial isolates. Diagn. Microbiol. Infect. Dis., 63:217–222.
21.
van DeldenC., BlumbergE.A.and AST Infectious Diseases Community of Practice. 2009. Multidrug resistant gram-negative bacteria in solid organ transplant recipients. Am. J. Transplant., 9,Suppl. 4:S27–S34.
22.
VisalliM.A., JacobsM.R., AppelbaumP.C.1998. Determination of activities of levofloxacin, alone and combined with gentamicin, ceftazidime, cefpirome, and meropenem, against 124 strains of Pseudomonas aeruginosa by checkerboard and time-kill methodology. Antimicrob. Agents Chemother., 42:953–955.
23.
WagnerT., SoongG., SokolS., SaimanL., PrinceA.2005. Effects of azithromycin on clinical isolates of Pseudomonas aeruginosa from cystic fibrosis patients. Chest, 128:912–919.
